Larimar Therapeutics (LRMR) Total Debt Growth (1y) (2015 - 2020)
Powered by 
Analysis
Larimar Therapeutics (LRMR) Total Debt Growth (1y) (2015 - 2020) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 6.99% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 3.27% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 0.10% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 25.75% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 0.00% |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | -32.59% |
| Dec 31, 2019 | -23.75% |
| Sep 30, 2019 | -27.75% |
| Jun 30, 2019 | -13.53% |
| Mar 31, 2019 | 2.97% |
| Dec 31, 2018 | 3.20% |
| Sep 30, 2018 | 1,803.47% |
| Jun 30, 2018 | 972.13% |
| Mar 31, 2018 | 612.02% |
| Dec 31, 2017 | 457.26% |
| Sep 30, 2017 | -70.64% |
| Jun 30, 2017 | -58.99% |
| Mar 31, 2017 | -50.39% |
| Dec 31, 2016 | -43.83% |
| Sep 30, 2016 | -38.64% |
| Jun 30, 2016 | -51.26% |
| Mar 31, 2016 | -40.38% |
| Dec 31, 2015 | -15.47% |
| Sep 30, 2015 | -6.18% |
| Jun 30, 2015 | 38.58% |